Antonio Portolés

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy

Laurian Zuidmeer, H. Huber, Ines Swoboda et al. · International Archives of Allergy and Immunology · 2015 · 105 citations · Full text

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale

N. Prieto, Ana Terleira, J M De Matias et al. · Journal of Psychopharmacology · 2008 · 97 citations

Effect of adverse drug reactions on length of stay in surgical intensive care units

Emilio Vargas, Ana Terleira, Fernando Hernando et al. · Critical Care Medicine · 2003 · 84 citations